

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 September 2010 (16.09.2010)

PCT

(10) International Publication Number
WO 2010/103111 A1

- (51) **International Patent Classification:**
A01K 45/00 (2006.01) G01N 33/52 (2006.01)
- (21) **International Application Number:**
PCT/EP2010/053210
- (22) **International Filing Date:**
12 March 2010 (12.03.2010)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
09155184.6 13 March 2009 (13.03.2009) EP
- (71) **Applicant (for all designated States except US):** VAN DE VEN BEHEER B.V. [NL/NL]; Meerheide 5, NL-5521 DZ Eersel (NL).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** DECUYPERE, Eddy [BE/BE]; Kasteelpark Arenberg 30, B-3001 Heverle (BE). FEY, Frank [NL/NL]; De Pinckart 24, NL-5670 AA Nuenen (NL).
- (74) **Agents:** DERKS, Wilhelmus et al.; Rembrandt Tower, 31st floor, Amstelplein 1, NL-1096 HA Amsterdam (NL).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHOD FOR AVIAN SEX DETERMINATION




Fig. 1

(57) **Abstract:** The invention relates to a method and apparatus for pre-hatch avian embryo sex determination. In particular, the invention relates to a non-invasive method and apparatus for in-ovo determining the sex of avian species while in the egg and allowing to sort the eggs into groups consisting primarily of either male or female embryos. The method comprises the steps of introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which antibody is labelled, allowing the labelled antibody to migrate to and bind with the sex specific antigen on the embryo, detecting binding of the labelled antibodies on the embryo using detection means positioned outside of the egg.

WO 2010/103111 A1

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

Method for avian sex determination

5

Field of the invention

[001] The invention relates to a method and apparatus for pre-hatch avian embryo sex determination. In particular, the invention relates to a non-invasive method and apparatus for determining the sex of avian species while in the egg and allowing to sort the eggs into groups consisting primarily of either male or female embryos.

10 The invention uses a non-invasive in-ovo measurement method to make the sex determination. In-ovo means measurement in the egg without having to take a sample from the egg.

Description of the Related Art

15 [002] Sex separation is an important aspect for all avian species production, but in particular for the broiler and essentially all egg layer and turkey production. For broilers and turkeys, sex separation allows a better suited management and feeding according to the needs of both sexes, which are somewhat different than the unisex rearing as done now in most cases. Essentially all commercial hatcheries of pullets that will become table egg laying hens use sex separation of flocks. Male chickens are culled at the hatchery, whereas female chickens are evidently destined for egg production.

20

[003] Currently, there are three methods available for sexing poultry. Day-old chicks can be sexed either by vent/cloaca sexing, or feather sexing methods. Alternatively, male and female chicks can be reared together until secondary sex characteristics become apparent, then the chicks can be separated based on sex. Vent/cloaca sexing relies on the visual identification of sex, based on the appearance of sex related anatomical structures. Feather sexing is based on feather characteristics that differ between male and female chicks, for example down colour pattern, and rapid/slow rate of growth of the wing feathers. The third method relies on the appearance of natural secondary sex characteristics, for example in males the combs and wattles will become larger than those on females.

25

[004] The vent/cloaca sex determination of day-old chicks is difficult and expensive. Identifying the sex of a bird requires highly skilled personnel. While easier to perform, feather sexing has the disadvantage of being limited to specific genetic crosses of birds. Sexing by secondary sex characteristics is the easiest method to perform but has the disadvantage of requiring birds of both sexes to be reared together for the first weeks after hatch which because of feed costs and feed conversion considerations can be more expensive to the hatchery than the expense of vent/cloaca sexing.

30

[005] Most importantly, because of the increasing optimization of meat production on one hand and egg production on the other hand, the male pullets of chicken breeds that are optimized for egg productions are no longer suitable or economically attractive for meat production. Therefore, over 500 million male chicks are destroyed every

year in the US and Europe only by gassing, electrocution or shredding. This is not only an economic problem, but it has also increasingly become an ethical problem.

5 [006] Clearly, the commercial hatchery industry has a need for a method that would allow birds to be sorted by sex at very early stage that does not rely on highly skilled individuals or on using specific genetic crosses of birds. Several methods have recently been developed.

10 [007] In US6512839 it is described that the sex of a hatchling is determined by ultrasound vent or cloaca scanning techniques. Although this may automate and reduce costs of the sex determination process, it still has the disadvantage that it is a post-hatching technique and therefore that the eggs must be hatched and that male chicks need to be destroyed.

15 [008] In US6029080 a method and apparatus is described for in-ovo determination of the sex of avian species comprising NMR imaging on the intact egg (non-invasive) to determine the presence of male or female sex organs in the embryo of the hatching eggs. The NMR signals are detected and converted to an image of the sex organs, which is interpreted by an image processing computer to identify at the sex of the embryo in the egg. Although it is a non-invasive technique, it has certain disadvantages. A particular disadvantage of this method is that it can only be applied in a late stage of development of embryo were the sex organs have been developed to the extent that they can be recognized. Apart from the fact that this is a waste of hatching capacity, the disadvantage is that the male eggs cannot be used for other purposes and that at this stage of development of the embryo the destruction may still raise ethical problems. Furthermore, the method is economically less attractive, first of all because NMR detection apparatus, certainly in combination with the imaging equipment, is very expensive and the technique is very complicated and because the eggs are preferably cooled to prevent movement of the embryo.

25 [009] In US7167579 it is described to determine the sex of an egg by taking an image of the egg, generating 2-dimensional contour image data from the image, extracting parameters from the contour image data and determining the sex of the chicken egg using said extracted parameters. It is considered that this method is not sufficiently reliable.

30 [0010] In WO2004/016812 the sex of an egg of an avian subject is determined by taking a sample of an egg, preferably from the allantoic fluid or amniotic fluid, and determining the presence of certain DNA sequences by hybridizing with a specified nucleic acid probe. The analysis of the hybridised sample includes a PCR amplification procedure.

35 [0011] Although this method is accurate and sufficiently reliable, it is highly elaborate, slow and expensive and therefore economically unattractive, but most important it is applied in a rather late stage of development where the amnion is already developed. The method is invasive, meaning that a sample must be taken from the egg, which

significantly increases the cost and increases the risk of creating infections and aberrations. Further, the method relies on very expensive and time-consuming nucleic acid amplification techniques like PCR. This means that this sex determination method can never have a high production capacity and is economically unattractive for commercial hatcheries.

5

[0012] The document WO2004/016812 also mentions the use of (monoclonal) antibodies to a peptide (and derivatives, fragments and synthetic constructs thereof capable of binding to the polypeptide) that is coded for by a sex specific DNA sequence. The method comprises contacting a sample extracted from said avian subject with the (preferably detectably labelled) antibody, and is ex-ovo. The document also mentions synthetic antibody constructs comprising a covalently linked moiety which provides the molecule with some desirable property in addition to antigen binding, for example a label (a detectable label, such as fluorescent or radioactive label) or a pharmaceutically active agent. Example 9 describes a method of producing monoclonal antibodies for identifying FAF peptides.

10

15 **Brief description of the invention:**

[0013] The problem underlying the invention is to provide a method and apparatus for pre-hatch avian embryo sex determination that can be applied in an early stage of development of the embryo, that is not invasive, meaning that no sample needs to be taken from the egg, and that is relatively easy, inexpensive and fast such that it is economically attractive for commercial hatcheries.

20

[0014] This problem is solved according to the invention by a method for pre-hatch determination of the sex of an embryo in an avian egg, comprising the steps of

- a. introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which antibody is labelled,
- b. allowing the labelled antibody to migrate to and bind with the sex specific antigen on the embryo,
- c. detecting binding of the labelled antibodies on the embryo using detection means positioned outside of the egg.

25

[0015] When incubating a fertilised egg, sex specific antigens on the embryo are formed at a very early stage of the development of the embryo in the blastodisc, which is located at one side of the egg yolk. The labelled antibodies will bind and a higher concentration of the labelled antibodies will be present, in or near the embryo. Labelled herein means having a functional group that acts as a label to allow detection of the antibody and the antibody-antigen combination. Male eggs can be identified by detecting the local concentration of labelled antibodies bound on the embryo or, in case labelled antibodies are used specific for female antigens, by the absence of such binding. The inventors have found a method for detecting the presence of such sex specific antigens using selected antibodies and detecting binding by detection means positioned outside of the egg that is a non-invasive, i.e. can be done without taking a sample from the egg.

30

35

Brief description of the drawings:

[0016] The features and advantages of the invention will be appreciated upon reference to the Figures 1 and 2. Figure 1 illustrates an egg positioned with the broad end upwards indicating: 1. Eggshell, 2. Outer membrane, 3. Inner membrane, 4. Chalaza, 5. Exterior albumen (outer thin albumen), 6. Middle albumen (inner thick albumen), 7. Vitelline membrane, 8. Nucleus of Pander, 9. Germinal disk (also referred to as blastoderm or blastodisc), 10. Yellow yolk, 11. White yolk, 12. Internal albumen, 13. Chalaza, 14. Air cell and 15. Cuticula and further illustrating detection means I comprising light source I.3 and detector I.2 penetrating the cuticula (15), eggshell (1) and outer membrane (2), but not inner membrane (3) ending in the air cell (14), detector I.2 measuring the emitted light (II.1) from labelled antibodies attached to the embryo, I.4 processes the data and determines if a local high concentration of labelled antibodies is present indicating the female embryo.

Figure 2 illustrates an egg with detection means I comprising light source I.3 positioned outside the egg and a detector I.2 also positioned outside the egg for measuring emitted light (II.1) from labelled antibodies near the embryo or blastodisc and evaluation means I.4 to determine and evaluate from the measured value binding of sex specific labelled antibodies indicative of the presence of an embryo.

[0017] Figure 3 illustrates an egg with detection means I comprising two light sources I.3.1 and I.3.2 positioned outside the egg at the top and bottom of the egg (along the central long axis) and a detectors I.1 and I.2 also positioned outside the egg for measuring emitted light from labelled antibodies. I.4 is used to determine and evaluate the ratio or difference of the measured values of the first and second detector to establish binding of sex specific labelled antibodies near the embryo indicative of the presence of an embryo.

Detailed description of the invention

[0018] The method comprises the step of introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which antibody is labelled. The antibody can be introduced into the egg in a variety of methods known in the art, preferably by injection into the egg, preferably by micro-injection using a needle or by micro-fluid injection using a high-pressure fluid jet or by osmosis.

[0019] A suitable injection method is described in WO2006/078499. This document describes a method to detect whether a pocket in a flat contains an egg or not or to detect injection tool position relative to the egg using a sensor (optical camera). This is part of an apparatus for injecting a substance in an egg or extracting substance from an egg, which is useful in the method according to the invention. Examples of substances injected include vaccines, antibiotics and vitamins.

[0020] The term labelled antibody is defined as an antibody having a functional group capable of detection. Preferably the labelled antibody can be detected by absorption or emission of light. Preferably the functional group is a luminescent group, more preferably it is a photo-luminescent group that can be excited by light to emit light at a

characteristic wavelength, most preferably a fluorescent or phosphorescent group. Alternatively, the functional group can be a magnetic nanoparticle, capable of being detected by magnetic or electric detection means.

5 [0021] The labelled antibody can be injected directly into the albumen or can be injected into the air cell and allowed to diffuse through the inner shell membrane into the albumen. The advantage of the first mentioned method is that the diffusion time and therefore the time between injection and detection is shorter. The advantage of the latter method is that disadvantages associated with the penetration of the inner membrane, like infections, can be reduced.

10 [0022] After the labelled antibody is introduced, it is allowed sufficient time to diffuse through the albumen and migrate to and bind with the selected sex specific antigen on the embryo. The diffusion rate of different labelled antibodies may vary. The skilled man can determine the appropriate diffusion time for a particular selected labelled antibody by measuring the time which is required to get a sufficiently strong detection signal in the measurement of the (relative) concentration of the labelled antibody.

15 [0023] The introduction can be done before or after the start of the incubation. In one embodiment of the method, the labelled antibody is introduced after the egg has been incubated for a time sufficient to allow a sufficient amount of antigens to be generated to be able to bind and detect the labelled antibodies. Typically, detection can take place between 2 and 10 days, preferably between 2 and 7 days more preferably between 2 and 5 days from the start of the incubation. This embodiment has the advantage that introduction and detection can be done in one handling step. In case the diffusion rate of a chosen labelled antibody is relatively slow, the labelled antibody is preferably injected before the start of the incubation to allow sufficient time for the labelled antibody to diffuse through the albumen.

20 [0024] The sex specific antigen on the embryo preferably is W chromosome specific protein antigen, or a ZZ chromosome specific protein antigen, or other indirectly expressed sex specific proteins. Suitable the sex specific antigen on the embryo can be selected from the group of W-specific gene/protein expressions; in particular CHD1W, ATP5A1W, Spin-W, ASW and most preferably FET-1 (female expressed transcript; trans-membrane domain) or of ZZ specific gene/protein expression; in particular DMRT1, SF1 and Dax1, or of the indirectly expressed sex-specific proteins, in particular AMH (Anti-Mullerian hormone).

30 [0025] The antibody can be a polyclonal antibody, a monoclonal antibody or a heavy chain antibody (nanobodies) or a fragment thereof. Heavy chain antibody (nanobodies) and antibody fragments have the advantages that they are smaller and have a higher diffusion rate. The antibodies can be produced on commercial scale in ways known in the art using the selected sex specific antigen.

35 [0026] An antibody can have as a part of its normal composition a functional group capable of detection or can be provided with a detectable functional group in ways known in the art. A functional group preferably is provided to

the constant region of the heavy chain, the Fc region (Fragment, crystallizable) of the antibody by binding the luminescent group to the Fc region. It is known in the art of immunofluorescence to label antibodies or antigens with fluorescent dyes. A suitable fluorescent dye is Fluorescein isothiocyanate (FITC), which has excitation and emission wavelengths of approximately 496 nm/521 nm. Like most fluorochromes, it is prone to photobleaching. Because of this newer derivatives of fluorescein such as Alexa 488 and DyLight 488, have been tailored for various chemical and biological applications where greater photostability, higher fluorescence intensity, or different attachment groups are needed. Other suitable and historically common fluorophores are derivatives of rhodamine (TRITC), coumarin, and cyanine. Other suitable detectable functional groups are recombinant proteins containing fluorescent protein domains, e.g. green fluorescent protein (GFP). Use of such "tagged" proteins allows much better localization and less disruption of protein function. Alternatively, the functional group is an enzyme which can be added in combination with a substance that the enzyme can convert to a detectable signal. Thus in the case of fluorescence, when light of the appropriate wavelength is shone upon the sample, any antigen/antibody complexes will fluoresce, with an intensity that is proportional to the amount thereof. The fluorescent signal can be detected by a detector.

[0027] The labelled antigen/antibody complexes are detected using detection means positioned outside of the egg. Outside the egg means outside of the inner membrane of the egg or more preferably outside of the entire egg. This is also referred to as non-invasive or in-ovo measurement, as opposed to invasive ex-ovo measurement which requires taking a sample from the egg. Positioning the light source outside the egg and illuminating through the egg shell results in significant light absorption and scattering, but is possible when the eggshell is at least partially transparent for the chosen wavelength. Absorption of light by the eggshell and by membranes is a feature of the egg that can be taken into account in the differential detection technique as described below. Scattering of light can be reduced by using an intense bundled light source and/or by applying a substance on the egg shell having a refractive index close to that of the egg shell.

[0028] There are various ways to determine (in-ovo) the presence or absence of binding of the labelled antibodies to the antigen on or near the embryo. The measurement can be based on the fact that the concentration of the labelled antibody will be higher near the embryo because it will (or will not in case of the other sex) bind to the sex specific antigens from the embryo. The position of the blastodisc or the embryo can be determined through the egg shell by optical or acoustic means. When the egg is positioned with the broader end upwards, i.e. with the air cell up (as in Figures 1 – 3), the blastodisc or embryo will move up closer towards the air cell. It is preferred to measure the detection signal from the blastodisc or embryo with the egg in this position through the air cell because there is less light scattering and absorption of the light and a better measurement signal can be obtained. In a simple embodiment, illustrated in Fig. 2, the labelled antibody concentration can be detected by measuring a concentration of the labelled antibody or a signal relating to said concentration close to the blastodisc and comparing the measured concentration or signal against a predetermined criterion. The criterion can be predetermined on unfertilised or unincubated eggs, for any chosen set of measurement conditions including but not limited to a specific choice for the label on the antibody, the chosen antibody/antigen combination, the chosen detection means, for example the

wavelength and intensity of detection light, the temperature etc. If the measured signal strength is above a predetermined criterion, the presence of antibody/antigen binding is determined.

5 [0029] In another more reliable method an internal reference measurement is provided in that the presence or absence of binding of the labelled antibodies to the embryo is detected by detecting inhomogeneity in the distribution of the labelled antibodies. The inhomogeneity can be determined by measuring local concentrations of the labelled antibody in a region close to the blastodisc and in a region remote from the blastodisc and determining the presence or absence of binding by comparing the difference or ratio of said measured concentrations against a predetermined criterion, preferably obtained from unfertilised or un-incubated eggs. In a particularly preferred method the region remote from the blastodisc preferably is at the side of the egg yolk opposite to the side where the blastodisc is located. In this way the egg yolk is positioned between the two places of measurement reducing the interference between the two measurements. Another big advantage is that the use of this relative measurement will cancel out the absorption spectrum of the eggshell. So, the result obtained on a white egg will be the same as obtained on a brown version.

15 [0030] In the most preferred embodiment, the antibody is labelled with a marker that is detectable by light, preferably a fluorescent group, and the detection means comprises a light source, a detector and optional filters to improve the signal to noise ratio of absorbed or emitted light, preferably a spectrometer. As illustrated in Figure 1, the detection means (I) preferably comprises a light source (I.3) illuminating the albumen, a first and second detector wherein a first detector (I.2) measures a labelled antibody concentration near the blastodisc, preferably by measuring light intensity of light emitted from the labeled antibody, and wherein a second detector (I.2) measures a labelled antibody concentration in a region remote from the blastodisc or embryo, preferably at the other side of the egg yolk. Evidently, each detector can be combined with an individual light source as indicated in Figure 3, or more than 2 detectors and/or light sources can be used. Preferably, the wavelength of the detection means is chosen such that the light of the light source and/or of the light emitted by the labelling group on the anti-body is absorbed by the egg yolk to isolate the measurement by the first detector near the blastodisc or embryo from the measurement by the second detector at the other side of the egg yolk and reduce the interference between the two measurements.

25 [0031] Alternatively, the egg is rotated along its length axis during which the concentration of the labelled antibody is measured preferably at a vertical position along its length axis where the blastodisc is positioned. Because the blastodisc and the embryo at early stage of development are not in the centre of the egg and isolated by the light absorbing egg yolk, a higher local concentration of the labelled antibody near the embryo will show up as a peak in the emitted light detection signal. Optionally a reference baseline is subtracted from a measurement of an unfertilised or un-incubated egg.

35 [0032] The light source and/or the detector can also be introduced into the egg through a small opening in the eggshell, preferably in the air cell, but preferably not through the inner shell membrane. This has the advantage of

reducing the scattering and absorption of light by the eggshell. This could be done by a very thin fiber optics probe comprising a light source and/or a detector probe and optional filters. The light source can be positioned outside the egg shell and the detector is introduced into the air cell of the egg. Alternatively, only the light source is introduced into the egg and the one or more detectors are positioned outside the egg shell. It is also possible to position the light source and/or the detector outside the egg in an embodiment wherein the wavelength of the excitation light and/or the emission light is not substantially absorbed or scattered by the egg-shell. The wavelength of the excitation light and/or the emission light is preferably selected between 700 and 2000 nm, preferably 700 – 1500, more preferably 700 - 1000 or between 610 and 630 nm. It was found that the egg shell is most transparent at these wavelengths.

10 [0033] In another aspect, the invention relates to a method and apparatus for in-ovo measurement, i.e. for measuring a labelled molecule in an egg without having to take a sample from the egg. These labelled molecules can be other sex specific molecules than the sex specific labelled antibodies as described herein. For example, it can be another sex specific reagent, for example RNA or DNA sequences to be introduced into the egg or it can be a molecule the egg produces itself, optionally after genetic modification of the egg (or chicken). The labelled molecule can also be another molecule that is introduced in an egg for other purposes, for example a medicament. The molecule is labelled with a functional group capable of in-ovo detection in a way similar as described herein for the labelled antibody. In particular, said method comprises

- 20 a. Providing an egg comprising labelled molecules, preferably sex specific molecules, more preferably sex specific antibodies, said molecules having a functional group detectable by in-ovo detection means, preferably a fluorescent or magnetic functional group,
- b. measurement of the concentration of the labelled molecules, preferably using a light source and a detector, more preferably a fluorescence spectrometer,
- c. evaluating the measured amounts of labelled molecules preferably for determining the sex of an embryo in the egg.

25 [0034] The invention also relates to an apparatus for pre-hatch determination of the sex of an embryo in an egg according to anyone of the method embodiments described above comprising

- 30 a. Means for introducing into the egg a labelled molecule, preferably a labelled antibody, preferably micro-injection means using a needle or micro-fluid injection means using a high-pressure fluid jet,
- b. Means for in-ovo measurement of concentration of the labelled molecule, preferably a light source and a detector, more preferably a fluorescence spectrometer.
- c. Means for evaluating from the measured amounts of the labelled molecule the presence or absence of binding of the labelled molecule on the embryo.

35 [0035] Preferably, the apparatus comprises a first and second detector wherein the first detector measures a labelled antibody concentration near the blastodisc and wherein the second detector measures a labelled antibody concentration in a region remote from the blastodisc, preferably at the other side of the egg yolk.

[0036] The invention also relates to anti-bodies for use in the method according to the invention that are modified with a functional group detectable by ex-ovo measurement, preferably a luminescent group, which anti-bodies preferably are polyclonal antibodies, monoclonal antibodies, heavy chain antibodies or fragments of it wherein the antigen binding side is chosen to match one or more sex specific antigens, preferably chosen from the group W-specific gene/protein expression CHD1W, ATP5A1W, Spin-W, ASW and most preferably FET-1 (female expressed transcript; trans-membrane domain) or of ZZ specific gene/protein expression, in particular DMRT1, SF1 and Dax1, or of the indirectly expressed sex-specific proteins, in particular AMH (Anti-Mullerian hormone).

10 Anti-Mullerian hormone was chosen as a suitable sex specific hormone. Antibodies for this hormone have already been produced Anti-Mullerian Hormone (antibody 213816, R & D Systems, Minneapolis, Minn.). The antibody is modified with green fluorescent protein (GFP). GFP is not phyto-toxic and is expected to be safe for use in the egg. Suitable techniques modifying the antibody with fluorescent groups are described in Gutowski, M., Carcenac, M., Pourquier, D., Larroque, C., Rouanet, P. and Pèlerin, A. (2001); "Intraoperative immunophotodetection for radical resection of cancer: evaluation in an experimental model", Clin. Cancer Res. 7, 1142–1148. The labelled antibody is injected into the egg before incubation using micro-injection technique described in WO2006/078499. The egg is positioned with the broad end upwards. After 3 days of incubation the egg is positioned in a measurement cell comprising 2 light sources and 2 detectors (see Figure 3). The light source for exciting the GFP emits light at a wavelength of 395 nm. The GFP emission peak is at 509 nm. The detectors for the emitted light are provided with filters to filter out the excitation light. The primary light source and detector is positioned near the embryo and the secondary (reference) light source and detector are positioned opposite to the embryo such that the egg yolk separates the primary and secondary detector. The ratio of the primary to secondary detection intensities is determined. The ratio of an un-incubated egg is determined and used as a reference measured in exactly the same measurement conditions. The incubated egg shows an increased ratio of the two detection signals compared to the un-incubated egg, indicative of preferential bonding of the labelled anti-body near the blastodisc and of the presence of a male embryo.

15

20

25

What is claimed is:

- 5 1. A method for pre-hatch determination of the sex of an embryo in an avian egg, comprising the steps of
a. introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which
antibody is labelled,
b. allowing the labelled antibody to migrate to and bind with the sex specific antigen on the embryo,
10 c. detecting binding of the labelled antibodies on the embryo using detection means positioned outside of
the egg.
- 15 2. The method according to claim 1, wherein the labelled antibody is injected into the egg, preferably by
micro-injection using a needle or by micro-fluid injection using a high-pressure fluid jet or by osmosis.
3. The method according to claim 1 or 2, wherein the labelled antibody is injected into the albumen.
4. The method according to claims 1 or 2, wherein the labelled antibody is injected into the air cell, and
diffuses through the inner shell membrane.
- 20 5. The method according to claim anyone of claims 1 to 4, wherein the labelled antibody is injected before the
start of the incubation.
6. The method according to claim anyone of claims 1 to 5, wherein the labelled antibody is injected and
allowed sufficient time to diffuse and migrate to and bind with the sex specific antigen on the embryo.
- 25 7. Method according to claim anyone of claims 1 to 6, wherein the sex specific antigen on the embryo is W
chromosome specific protein antigen, or a ZZ chromosome specific protein antigen, or other indirectly
expressed sex specific proteins.
- 30 8. A method according to anyone of claims 1 to 7, wherein detection takes place between 2 and 10 days,
preferably between 2 and 7 days more preferably between 2 and 5 days from incubation.
9. Method according to claim anyone of claims 1 to 8, wherein the sex specific antigen on the embryo is
selected from the group of W-specific gene/protein expression, in particular CHD1W, ATP5A1W, Spin-W,
35 ASW and most preferably FET-1 (female expressed transcript; trans-membrane domain) or of ZZ specific
gene/protein expression, in particular DMRT1, SF1 and Dax1, or of the indirectly expressed sex-specific
proteins, in particular AMH (Anti-Mullerian hormone).

10. The method according to anyone of claims 1 to 9, wherein the antibody is a polyclonal antibody, a monoclonal antibody or a heavy chain antibody or a fragment thereof.
- 5 11. The method according to anyone of claims 1 to 10, wherein the presence or absence of binding of the labelled antibodies to the embryo is detected by measuring a concentration of the labelled antibody close to the blastodisc and comparing the measured concentrations against a predetermined standard criterion preferably obtained from unfertilised or un-hatched eggs.
- 10 12. The method according to anyone of claims 1 to 10, wherein the presence or absence of binding of the labelled antibodies to the embryo is detected by detecting inhomogeneity in the distribution of the labelled antibodies.
- 15 13. The method according to claim 12, wherein the inhomogeneity is determined by measuring local concentrations of the labelled antibody in a region close to the blastodisc and in a region remote from the blastodisc and determining the presence or absence of binding by comparing the difference or ratio of said measured concentrations against a predetermined criterion, preferably obtained from unfertilised or un-hatched eggs.
- 20 14. The method according to claims 12 or 13 wherein the region remote from the blastodisc is at the side of the egg yolk opposite to the side where the blastodisc is located.
- 25 15. The method according to anyone of claims 1 to 11, wherein the antibody is labelled with a marker detectable by light, preferably a fluorescent group.
- 30 16. The method according to anyone of claims 1 to 15, wherein the detection means comprises a light source, a detector and optional filters to improve the signal to noise ratio of absorbed or emitted light, preferably a spectrometer.
- 35 17. The method according to claim 15 or 16, comprising a first and second detection means wherein a first detector measures a labelled antibody concentration near the blastodisc and wherein a second detector measures a labelled antibody concentration in a region remote from the blastodisc, preferably at the other side of the egg yolk.
18. The method according to claim 16 or 17, wherein the wavelength of the detection means is chosen such that the light of the light source and/or of the light emitted by the labelling group on the anti-body is absorbed by the egg yolk to isolate measurement by the first detector near the blastodisc from the measurement by the second detector at the other side of the egg yolk.

19. The method according to anyone of claims 16 to 18, wherein the light source and/or the detector are introduced into the egg through a small opening in the eggshell, preferably in the air cell, but preferably not through the inner shell membrane.
- 5
20. The method according to anyone of claims 16 - 18, wherein the light source and/or the detector are positioned outside the egg and wherein the wavelength of the excitation light and/or the emission light is not substantially absorbed or scattered by the egg-shell.
- 10
21. The method according to claim 20, wherein the wavelength of the excitation light and/or the emission light is selected between 700 and 2000 nm, preferably 700 – 1500, more preferably 700 - 1000 or between 610 and 630 nm.
- 15
22. Anti-bodies for use in the method according to any one of claims 1 – 21, preferably polyclonal antibodies, monoclonal antibodies, heavy chain antibodies or fragments of it wherein the antigen binding side is chosen to match one or more sex specific antigens, preferably chosen from the group W-specific gene/protein expression CHD1W, ATP5A1W, Spin-W, ASW and most preferably FET-1 (female expressed transcript; trans-membrane domain) or of ZZ specific gene/protein expression, in particular DMRT1, SF1 and Dax1, or of the indirectly expressed sex-specific proteins, in particular AMH (Anti-Mullerian hormone).
- 20
23. A method for in-ovo measurement of labelled molecules comprising
- a. Providing an egg comprising labelled molecules, preferably sex specific molecules, more preferably sex specific antibodies, said molecules having a functional group detectable by in-ovo detection means, preferably a fluorescent group,
- 25
- b. in-ovo measurement of the concentration of the labelled molecules, preferably using a fluorescence spectrometer,
- c. evaluating the measured amounts of labelled molecules, preferably for determining the sex of an embryo in the egg.
- 30
24. The method according to anyone of claim 23 for measurement of labelled molecules near the embryo or blastodisc, wherein the egg is preferably positioned with the broad end upwards and the concentration of the labelled molecule is measured close to the blastodisc or embryo through the air cell.
- 35
25. The method according to anyone of claim 24, wherein in step c) the measured concentration is evaluated by
- 1) comparing the measured concentration with a predetermined standard criterion preferably obtained from a reference egg or 2) comparing the measured concentration with a second measured concentration in a

region remote from the blastodisc, preferably at the side of the egg yolk opposite to where the blastodisc is located.

- 5 26. The method according to anyone of claim 23 or 25, wherein a light source and/or a detector are introduced into the egg through a small opening in the eggshell, preferably in the air cell, but not through the inner shell membrane.
- 10 27. Apparatus for pre-hatch determination of the sex of an embryo in an egg comprising
- a. Means for introducing into the egg a labelled molecule, preferably a labelled antibody, preferably micro-injection means using a needle or micro-fluid injection means using a high-pressure fluid jet,
 - b. Means for in-ovo measurement of concentration of the labelled molecule, preferably a light source and a detector, more preferably a fluorescence spectrometer.
 - 15 c. Means for evaluating from the measured amounts of the labelled molecule the presence or absence of binding of the labelled molecule on the embryo.
- 20 28. Apparatus according to claim 22 comprising a first and second detector wherein the first detector measures a concentration near the blastodisc and wherein the second detector measures a concentration in a region remote from the blastodisc, preferably at the other side of the egg yolk.




Fig. 1




Fig. 2




Fig. 3

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/053210

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A01K45/00 G01N33/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 A01K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, Sequence Search, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2006/078499 A2 (EMBRX INC [US]; HEBRANK JOHN H [US]) 27 July 2006 (2006-07-27) claims 26-31	1-22
Y	RAAB U ET AL: "Endoglin is expressed in the chicken vasculature and is involved in angiogenesis" FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 459, no. 2, 8 October 1999 (1999-10-08), pages 249-254, XP004260356 ISSN: 0014-5793 abstract	1-22

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 May 2010

Date of mailing of the international search report

23/08/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Vollbach, Silke

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/053210

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/016812 A1 (ROSLIN INST EDINBURGH [GB]; CLINTON MICHAEL [GB]) 26 February 2004 (2004-02-26) page 3 - page 4	1-22
Y	MORRISH BRONWYN C ET AL: "Vertebrate sex determination: Many means to an end" REPRODUCTION (CAMBRIDGE), vol. 124, no. 4, October 2002 (2002-10), pages 447-457, XP002569740 ISSN: 1470-1626 abstract figure 2	1-22
Y	KOYAMA YOSHIYUKI ET AL: "Sequence analysis of full-length cDNA of sex chromosome-linked novel gene 2d-2F9 in Gallus gallus" BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 71, no. 2, February 2007 (2007-02), pages 561-570, XP002569741 ISSN: 0916-8451 the whole document	1-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2010/053210

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see additional sheet(s)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-22

A method for pre-hatch determination of the sex of an embryo
in an avian egg

2. claims: 23-26

A method for in-ovo measurement of labelled molecules

3. claims: 27, 28

for pre-hatch determination of the sex of an embryo in an
egg

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2010/053210

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 2006078499	A2	27-07-2006	AU 2006206753 A1	27-07-2006
			BR PI0606581 A2	21-07-2009
			CA 2595027 A1	27-07-2006
			CA 2683897 A1	27-07-2006
			CN 101404876 A	08-04-2009
			EP 1838146 A2	03-10-2007
			JP 2008530983 T	14-08-2008
			KR 20070091021 A	06-09-2007
WO 2004016812	A1	26-02-2004	AU 2003251058 A1	03-03-2004
			CA 2495730 A1	26-02-2004
			EP 1529118 A1	11-05-2005
			US 2006160080 A1	20-07-2006